AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+16.34%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$645M
AUM Growth
+$645M
(+1.5%)
Cap. Flow
-$54.3M
Cap. Flow
% of AUM
-8.43%
Top 10 Holdings %
Top 10 Hldgs %
44.28%
Holding
108
New
9
Increased
21
Reduced
28
Closed
17
Top Buys
| 1 |
Nuvalent
NUVL
|
$14.1M |
| 2 |
Alkermes
ALKS
|
$9.8M |
| 3 |
Viridian Therapeutics
VRDN
|
$8.53M |
| 4 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$8.43M |
| 5 |
Wave Life Sciences
WVE
|
$8.41M |
Top Sells
Sector Composition
| 1 | Healthcare | 92.7% |
| 2 | Financials | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
BridgeBio Pharma
BBIO
$9.91B
| $7.64M | 1.04% |
300,000
+200,000
| +200% | +$5.09M |
|
|
CLYM
27
Climb Bio, Inc. Common Stock
CLYM
$165M
| $7.64M | 1.04% |
1,500,000
-170,661
| -10% | -$869K |
|
28
Axsome Therapeutics
AXSM
$6.09B
| $7.19M | 0.98% |
80,000
| – | – |
|
29
Erasca
ERAS
$406M
| $6.82M | 0.93% |
2,499,431
| – | – |
|
30
Geron
GERN
$893M
| $6.81M | 0.93% |
1,500,000
| – | – |
|
31
Perspective Therapeutics
CATX
$251M
| $6.68M | 0.91% |
500,000
-50,000
| -9% | -$668K |
|
32
Immunovant
IMVT
$2.91B
| $6.41M | 0.88% |
225,000
-121,088
| -35% | -$3.45M |
|
33
Arrowhead Research
ARWR
$3.84B
| $6.3M | 0.86% |
325,000
+275,000
| +550% | +$5.33M |
|
34
Vaxcyte
PCVX
$4.17B
| $5.71M | 0.78% |
50,000
-10,000
| -17% | -$1.14M |
|
35
Arvinas
ARVN
$580M
| $5.54M | 0.76% |
+225,000
| New | +$5.54M |
|
36
Terns Pharmaceuticals
TERN
$651M
| $5M | 0.68% |
+600,000
| New | +$5M |
|
|
SWTX
37
DELISTED
SpringWorks Therapeutics
SWTX
| $4.73M | 0.64% |
147,500
+77,501
| +111% | +$2.48M |
|
38
Cullinan Oncology
CGEM
$456M
| $4.42M | 0.6% |
263,817
| – | – |
|
39
Celldex Therapeutics
CLDX
$1.57B
| $4.25M | 0.58% |
125,000
-350,400
| -74% | -$11.9M |
|
40
Mineralys Therapeutics
MLYS
$1.94B
| $4.24M | 0.58% |
350,000
+22,041
| +7% | +$267K |
|
41
Insmed
INSM
$30.3B
| $3.65M | 0.5% |
50,000
-75,000
| -60% | -$5.48M |
|
|
PCSC
42
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $3.51M | 0.48% |
350,000
| – | – |
|
43
NextCure
NXTC
$13.3M
| $3.15M | 0.43% |
191,883
+51,220
| +36% | +$842K |
|
44
Savara
SVRA
$591M
| $2.97M | 0.41% |
700,000
-846,850
| -55% | -$3.59M |
|
45
Nkarta
NKTX
$149M
| $2.94M | 0.4% |
650,000
+450,000
| +225% | +$2.03M |
|
46
Mirum Pharmaceuticals
MIRM
$3.75B
| $2.93M | 0.4% |
75,000
-80,000
| -52% | -$3.12M |
|
47
Immatics
IMTX
$662M
| $2.85M | 0.39% |
250,000
-50,000
| -17% | -$571K |
|
|
BBOT
48
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$779M
| $2.61M | 0.36% |
250,000
| – | – |
|
49
Context Therapeutics
CNTX
$75.6M
| $2.59M | 0.35% |
1,321,153
-297,987
| -18% | -$584K |
|
|
NARI
50
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $2.47M | 0.34% |
60,000
-140,000
| -70% | -$5.77M |
|